Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
2.45%200.391.2%$531.71m
GILDGilead Sciences, Inc.
3.39%75.250.9%$475.38m
BIIBBiogen Inc.
1.64%333.811.3%$390.98m
CELGCelgene Corporation
2.04%83.501.2%$346.10m
ILMNIllumina, Inc.
2.14%320.103.5%$304.01m
REGNRegeneron Pharmaceuticals, Inc.
4.44%394.312.6%$238.63m
ALXNAlexion Pharmaceuticals, Inc.
4.68%127.182.0%$225.15m
VRTXVertex Pharmaceuticals Incorporated
3.24%183.401.9%$217.30m
SRPTSarepta Therapeutics, Inc.
4.53%137.2916.4%$178.87m
AAgilent Technologies, Inc.
2.24%67.101.5%$161.01m
BMRNBioMarin Pharmaceutical Inc.
4.97%104.394.4%$142.09m
LGNDLigand Pharmaceuticals Incorporated
6.36%212.8023.3%$122.70m
VKTXViking Therapeutics, Inc.
7.61%15.280.9%$120.55m
NKTRNektar Therapeutics
2.81%50.465.6%$112.12m
EXASExact Sciences Corporation
1.32%66.6425.3%$104.38m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.